The protoxin Cry1Ac of Bacillus thuringiensis improves the protection conferred by intranasal immunization with Brucella abortus RB51 in a mouse model

Brucellosis is a zoonotic disease affecting many people and animals worldwide. Preventing this infection requires improving vaccination strategies. The protoxin Cry1Ac of Bacillus thuringiensis is an adjuvant that, in addition to increasing the immunogenicity of different antigens, has shown to be protective in different models of parasitic infections. The objective of the present study was to test whether the intranasal co-administration of pCry1Ac with the RB51 vaccine strain of Brucella abortus confers protection against an intranasal challenge with the virulent strain B. abortus 2308 in BALB/c mice. The results showed that co-administration of pCry1Ac and RB51, increased the immunoprotection conferred by the vaccine as evidenced by the following: (1) decrease of the splenic bacterial load when challenged intranasally with the virulent strain; (2) greater in vivo cytotoxic activity in response to the transference of previously infected cells; (3) further proliferation of cytotoxic TCD8+ cells in response to stimulation with heat-inactivated bacteria; (4) increased production of TNF-α and IFN-γ; and (5) significant IgG2a response. These results indicate that the use of the Cry1Ac protein as a mucosal adjuvant via the intranasal route can be a promising alternative for improving current RB51 vaccine against brucellosis.     

Protectivity conferred by immunization with intranasal recombinant outer membrane protein H from Pasteurella multocida serovar A:1 in chickens

Recombinant outer membrane protein H (rOmpH) is a potential fowl cholera vaccine candidate. The present study was aimed at developing rOmpH formulations for intranasal administration. The rOmpH was purified and formulated with either Escherichia coli enterotoxin B (LTB) or CpG oligodeoxynucleotides (ODN) as an adjuvant. Antibody responses in chickens intranasally immunized with rOmpH in combination with 2 different adjuvants were significantly increased (P<0.05) post immunization. Chicken survival rates showed that rOmpH formulated with ODN and LTB elicited 90% and 70% protection, respectively. Our findings indicated that rOmpH formulated with ODN elicited protection better than that formulated with LTB. Therefore, the vaccines formulations in the present study can be considered new intranasal vaccine formulations for fowl cholera in chickens.     

膜分离法纯化浓缩的猪细小病毒灭活疫苗效果研究

为了研究纯化浓缩的猪细小病毒灭活疫苗的免疫效果,应用微滤/超滤管式陶瓷膜分离系统对猪细小病毒细胞收获液进行纯化浓缩,使浓缩液病毒平均含量由10~(4.7)TCID_(50)/mL提高到10~(6.5)TCID_(50)/mL;将纯化浓缩的病毒液经检验合格后,进行甲醛灭活,与注射用矿物白油佐剂制成油包水灭活疫苗;按照猪细小病毒灭活疫苗的质量标准,对制备的灭活疫苗进行检验与免疫效果试验。结果显示:纯化浓缩的猪细小病毒液杂蛋白去除率平均达到71.6%左右;制备的三组灭活疫苗检验均合格;免疫至63 d时,免疫猪体内抗猪细小病毒抗体(HI)水平分别为:纯化浓缩的灭活疫苗平均高达9.62 log_2稀释倍数,常规疫苗平均为8.78log_2稀释倍数,差异显著(P0.05)。试验表明:疫苗病毒细胞收获液进行膜纯化技术处理后,免疫效果显著优于未经纯化的常规灭活疫苗。     

猪繁殖与呼吸综合征疫苗的研究进展

猪繁殖与呼吸综合征(PRRS)是由猪繁殖与呼吸综合征病毒(PRRSV)引起的严重危害世界养猪业的一种传染病,该病可造成猪的繁殖障碍、呼吸系统病症与生长受阻。本文着眼于PRRSV疫苗的免疫原性、保护效力和安全性,涉及市场上现有的商品化疫苗与已报道的处于试验阶段的相关疫苗研究成果,以期为PRRSV的防控与疫苗研发提供有益的参考。     

寄生虫半胱氨酸蛋白酶核酸疫苗的研究进展与应用前景

就寄生虫半胱氨酸蛋白酶的一些生理生化与免疫学性质进行了概括,阐述了该酶与宿主免疫应答之间的作用关系,证明了该酶具有作为研制高效核酸疫苗的条件,同时综述了寄生虫半胱氨酸蛋白酶核酸疫苗的发展以及应用前景。     

狂犬病灭活疫苗CVS-11株对牛的免疫效果

野生狐和貉狂犬病流行于新疆、内蒙古和黑龙江地区,是当地牛、羊和骆驼等家畜狂犬病的主要传染源。在国内尚无野生动物口服疫苗的前提下,对家畜进行狂犬病灭活疫苗接种,具有重要的公共卫生学意义。本研究利用国产犬用狂犬病灭活疫苗(CVS-11株)对牛进行了免疫效果和安全性评价。以不同剂量疫苗肌内注射免疫成年牛350头,通过比较免疫后狂犬病病毒中和抗体水平和持续期,确定犬用狂犬病灭活疫苗(CVS-11株)在牛的最佳免疫剂量为1次性注射2剂量疫苗,免疫持续期为1年。结果表明,犬用狂犬病灭活疫苗(CVS-11株)免疫牛时,具有较高的免疫原性和安全性,适用于牛等大型动物的狂犬病注射免疫。     

藏北草原牧民可持续生计分析—以班戈县为例

运用实地调查的方法,对藏北草原牧业户和兼业户进行比较分析和回归分析,以期提高人们对藏北草原牧民生计状况的认识,并对藏北草原牧民生活水平提升和收入增长提供一定的参考依据。结果表明:班戈县牧业户呈现"低质化"特征;兼业户的资本禀赋要好于牧业户;拥有较多自然资本和经济资本的牧户习惯于以单纯依靠牧业收入作为其生计策略;拥有较多人力资本、物质资本和社会资本的牧户更愿意选择多种经营方式来获取更多收入;物质资本对牧户生计策略的影响最为显著,社会资本显著程度不高,而人力资本存量偏低。总体来说,牧民生计在提升藏北草原牧民生活水平和促进牧民收入提高过程中显得更加急迫和重要。     

Immunization of BALB/c mice with Brucella abortus 2308ΔwbkA confers protection against wild-type infection

Brucellosis is a zoonotic disease that causes animal and human diseases. Vaccination is a major measure for prevention of brucellosis, but it is currently not possible to distinguish vaccinated animals from those that have been naturally infected. Therefore, in this study, we constructed the Brucella (B.) abortus 2380 wbkA mutant (2308ΔwbkA) and evaluated its virulence. The survival of 2308ΔwbkA was attenuated in murine macrophage (RAW 264.7) and BALB/c mice, and it induced high protective immunity in mice. The wbkA mutant elicited an anti-Brucella-specific immunoglobulin G response and induced the secretion of gamma interferon. Antibodies to 2308ΔwbkA could be detected in sera from mice, implying the potential for use of this protein as a diagnostic antigen. The WbkA antigen would allow serological differentiation between infected and vaccinated animals. These results suggest that 2308ΔwbkA is a potential attenuated vaccine against 16M. This vaccine will be further evaluated in sheep.